Literature DB >> 23870185

Letter to the editor.

Joachim Osur, Traci L Baird, Brooke A Levandowski, Emily Jackson, Daniel Murokora.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23870185      PMCID: PMC3717091          DOI: 10.3402/gha.v6i0.21787

Source DB:  PubMed          Journal:  Glob Health Action        ISSN: 1654-9880            Impact factor:   2.640


× No keyword cloud information.
We sincerely appreciate Moran and colleagues’ contributions to the discussion about implementing misoprostol for postabortion care (PAC). Many organizations are now working on this issue and sharing information and best practices, as Moran et al. did in their letter, is beneficial to the whole field. They underscore key issues, especially around stakeholder support and sustainable availability of misoprostol. Their data from Zimbabwe about providers’ perception of women's preferences are significant, both because those providers also see the need for women to have options for care, and because it is another example – like ours – of providers being the voices for women. Currently, data related to women's perspectives regarding misoprostol for PAC (MPAC) are limited to acceptability of this service (1–5). While acceptability of MPAC is clearly necessary, understanding women's preferences for PAC treatment modalities is an important area for future research, so services can best meet women's needs. Moran et al. additionally highlight the importance of ensuring that information presented to patients regarding MPAC is not only scientifically accurate but also culturally appropriate. We support Moran et al.'s point about introducing misoprostol in sites which do not offer manual vacuum aspiration (MVA) and add that a functional referral system must be established for women who may choose vacuum aspiration, who are not eligible for misoprostol, or those who may develop complications that require vacuum aspiration as an intervention. This is consistent with guidance by the World Health Organization (6) but was not part of the design in Kenya where implementation was being done on a pilot basis and before WHO made the recommendation. The model that is promising for the future is to have a referral centre with both services (MVA and MPAC) being fed with referrals from smaller centres that provide MPAC only. Given that misoprostol is inexpensive, stable at room temperature, and easy to use, we expect further expansion of MPAC into sites where it is the sole method available in the future. There is much to be learned by studying such an implementation, particularly across different facilities and among different cadres of health providers.
  5 in total

1.  A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion.

Authors:  Andrew Weeks; Godfrey Alia; Jennifer Blum; Beverly Winikoff; Paul Ekwaru; Jill Durocher; Florence Mirembe
Journal:  Obstet Gynecol       Date:  2005-09       Impact factor: 7.661

2.  Misoprostol for treatment of incomplete abortion at the regional hospital level: results from Tanzania.

Authors:  B Shwekerela; R Kalumuna; R Kipingili; N Mashaka; E Westheimer; W Clark; B Winikoff
Journal:  BJOG       Date:  2007-09-05       Impact factor: 6.531

3.  Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care? Results from a randomised trial in Burkina Faso, West Africa.

Authors:  B Dao; J Blum; B Thieba; S Raghavan; M Ouedraego; J Lankoande; B Winikoff
Journal:  BJOG       Date:  2007-09-05       Impact factor: 6.531

4.  Comparison of misoprostol and manual vacuum aspiration for the treatment of incomplete abortion.

Authors:  C Bique; M Ustá; B Debora; E Chong; E Westheimer; B Winikoff
Journal:  Int J Gynaecol Obstet       Date:  2007-07-03       Impact factor: 3.561

5.  Introducing misoprostol for the treatment of incomplete abortion in Nigeria.

Authors:  Talemoh Dah; Akinsewa Akiode; Paschal Awah; Tamara Fetters; Mathew Okoh; Innocent Ujah; Ejike Oji
Journal:  Afr J Reprod Health       Date:  2011-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.